MINDCURE to Participate in the H.C. Wainwright Bioconnect Conference in January 2022
Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) announced that President & CEO Kelsey Ramsden will present virtually at the H.C. Wainwright Bioconnect Conference from January 10-13, 2022. The presentation will be available on-demand starting January 10 at 7:00 a.m. ET. Additionally, the company granted 350,000 stock options to employees and consultants with exercise prices of $0.195 and $0.215 per share. MINDCURE is focused on advancing digital therapeutics and researching psychedelic compounds for mental health improvement.
- None.
- None.
VANCOUVER, BC, Jan. 6, 2022 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for psychedelics, today announced that President & Chief Executive Officer, Kelsey Ramsden, will present virtually at the H.C. Wainwright Bioconnect Conference taking place on January 10-13, 2022.
A webcast of MINDCURE's presentation will be available on-demand from Monday, January 10th at 7:00a.m. ET via this link: https://journey.ct.events/view/0f297ecc-702f-45d2-9952-45218d7559f1. A recording of the webcast can be viewed through the above link for 90 days.
To schedule a one-on-one meeting with MINDCURE's management team, please contact KCSA Strategic Communications at mindcureIR@kcsa.com.
The Company also announces it has granted a total of 350,000 stock options to certain employees and consultants pursuant to the terms of the Company's long term incentive plan ("Plan"). The stock options are exercisable: 250,000 at a price of
About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on LinkedIn, Facebook, Twitter, and Instagram.
On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995
Forward-Looking Information
Certain information presented in this news release may constitute "forward-looking information" within the meaning of applicable securities laws regarding MINDCURE and its business. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors could cause actual results to differ materially from the Company's expectations, including the risks detailed from time to time in the Company's public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.
The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/mindcure-to-participate-in-the-hc-wainwright-bioconnect-conference-in-january-2022-301455325.html
SOURCE Mind Cure Health Inc.
FAQ
When is the H.C. Wainwright Bioconnect Conference where Mind Cure will present?
How can I watch Mind Cure's presentation at the conference?
What details are there about the stock options granted by Mind Cure?
What is Mind Cure Health focused on?
